<DOC>
	<DOCNO>NCT01776424</DOCNO>
	<brief_summary>The primary purpose study evaluate whether treatment rivaroxaban aspirin rivaroxaban alone well aspirin alone prevention heart attack , stroke cardiovascular death patient coronary peripheral artery disease .</brief_summary>
	<brief_title>Rivaroxaban Prevention Major Cardiovascular Events Coronary Peripheral Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Coronary peripheral artery disease Patients coronary artery disease must also meet least one following : Age â‰¥65 , Age &lt; 65 documented atherosclerosis revascularization involve least 2 vascular bed , least 2 additional risk factor Need dual antiplatelet therapy , nonaspirin antiplatelet therapy oral anticoagulant therapy Stroke within 1 month history hemorrhagic lacunar stroke Severe heart failure know ejection fraction &lt; 30 % New York Heart Association ( NYHA ) class III IV symptom Estimated glomerular filtration rate ( eGFR ) &lt; 15 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cardiovascular event</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Xarelto</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>blood thinner</keyword>
	<keyword>aspirin</keyword>
	<keyword>ASA</keyword>
	<keyword>CAD</keyword>
	<keyword>coronary disease</keyword>
	<keyword>artery disease</keyword>
	<keyword>coronary artery bypass graft</keyword>
	<keyword>stroke</keyword>
	<keyword>heart attack</keyword>
	<keyword>angina</keyword>
	<keyword>arterial vascular disease</keyword>
	<keyword>transient ischemic attack</keyword>
	<keyword>TIA</keyword>
	<keyword>heart disease</keyword>
</DOC>